sec filing
FA
NASDAQ · FATE
Fate Therapeutics, Inc.
Healthcare · Biotechnology
$2.32
Up+$0.02 (+0.87%)
Updated Oct 5, 2026, 6:19 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 128M
- P/E ratio
- -0.85
- Dividend yield
- 0.00%
- 52-week range
- $0.95 – $3.23
- Volume
- 658.02K
- Avg. volume
- 2.11M
Price performance · FATE
FATE price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
FATE closed at $2.32 after 19 trading sessions, down 7.20% for the selected period.
- Last close
- $2.32
- Period change
- -7.20%
- Period low
- $2.30
- Period high
- $2.58
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $2.34 | $2.36 | $2.27 | $2.32 | 658.02K |
| Oct 1, 2026 | $2.37 | $2.39 | $2.285 | $2.30 | 812.98K |
| Sep 30, 2026 | $2.40 | $2.495 | $2.355 | $2.37 | 1.08M |
| Sep 29, 2026 | $2.37 | $2.41 | $2.29 | $2.38 | 1.44M |
| Sep 28, 2026 | $2.30 | $2.42 | $2.27 | $2.38 | 1.16M |
| Sep 25, 2026 | $2.34 | $2.465 | $2.27 | $2.35 | 3.39M |
| Sep 24, 2026 | $2.43 | $2.43 | $2.27 | $2.33 | 1.18M |
| Sep 23, 2026 | $2.57 | $2.585 | $2.43 | $2.43 | 909.7K |
| Sep 22, 2026 | $2.55 | $2.63 | $2.51 | $2.58 | 1.66M |
| Sep 21, 2026 | $2.52 | $2.575 | $2.44 | $2.53 | 1.27M |
| Sep 18, 2026 | $2.59 | $2.6085 | $2.475 | $2.53 | 4.19M |
| Sep 17, 2026 | $2.48 | $2.685 | $2.46 | $2.52 | 5.14M |
| Sep 16, 2026 | $2.35 | $2.465 | $2.345 | $2.44 | 1.28M |
| Sep 15, 2026 | $2.33 | $2.40 | $2.27 | $2.35 | 828.37K |
| Sep 14, 2026 | $2.30 | $2.40 | $2.28 | $2.34 | 645.66K |
| Sep 11, 2026 | $2.36 | $2.39 | $2.30 | $2.31 | 742.39K |
| Sep 10, 2026 | $2.42 | $2.45 | $2.28 | $2.33 | 751.11K |
| Sep 9, 2026 | $2.48 | $2.52 | $2.4243 | $2.44 | 553.58K |
| Sep 8, 2026 | $2.45 | $2.55 | $2.395 | $2.50 | 1.92M |
Latest FATE news
The latest Smart Investors Daily articles mentioning FATE.
Stock researchCompany · Earnings
Company
Market Activity
Research & News
Loading stock research…

